98%
921
2 minutes
20
IntroductionThe rising costs, complexity, and ethical challenges of anticancer therapies have created an urgent need for structured frameworks to ensure clinical efficacy, cost-effectiveness, and equitable access. Oncology stewardship (OS) has emerged as a promising model to optimize oncology pharmacotherapy and resource allocation. However, the lack of a unified model for OS implementation and evaluation represents a critical gap. This review addresses this by synthesizing emerging practices and policy considerations to inform the structured integration of OS into oncology systems.MethodsThis narrative review followed the conceptual synthesis approach outlined by Baumeister & Leary (1997) and Green et al. (2006), to develop a coherent understanding of OS as a clinical and policy framework. English-language sources published between 2001 and 2025 were purposively selected from PubMed, Scopus, and Google Scholar. Thematic analysis was used to organize and interpret findings.ResultsFive core domains were identified: (1) systemic drivers necessitating OS, including rising costs, drug shortages, safety concerns, and ethical considerations; (2) core operational strategies such as pre-authorization, dose optimization, site-of-care transitions, biosimilar adoption, and biomarker-guided therapy; (3) the governance role of Pharmacy and Therapeutics Committees in formulary management and clinical decision-making; (4) structural components and outcome metrics to assess the clinical, economic, and operational impact of OS; and (5) implementation barriers such as stakeholder resistance, limited infrastructure, and regulatory gaps. The review also highlights that although many OS initiatives demonstrate clinical and financial promise, their success is often limited by voluntary, fragmented implementation and a lack of standardized evaluation.ConclusionOS offers a critical but underutilized framework for improving the quality, safety, and sustainability of oncology care. While several operational models and interventions have shown promise, their fragmented adoption and weak regulatory support hinder scalability. Advancing OS will require national-level policy integration, investment in implementation infrastructure, and the development of standardized metrics to guide evaluation and accountability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/10781552251372492 | DOI Listing |
J Pediatric Infect Dis Soc
September 2025
Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece.
Background: Critically ill pediatric patients admitted to the PICU are highly vulnerable to infections, including invasive fungal diseases and antifungal agents are frequently prescribed. Little is known about antifungal usage in PICUs across Europe.
Methods: A multinational 3-month weekly point-prevalence study for measuring antifungal drug use was organized.
J Infect Dev Ctries
August 2025
Department of Infectious Diseases and Clinical Microbiology, Etlik City Hospital, Ankara, Turkey.
Introduction: Both aging and malignancy are associated with an increased risk of infections, including bloodstream infections. Despite their clinical significance, research concentrating on the epidemiology, outcomes, and risk factors influencing mortality in older cancer patients is still limited. This study aims to examine the epidemiology of bloodstream infections and factors contributing to mortality among older cancer patients.
View Article and Find Full Text PDFJ Infect Dev Ctries
August 2025
Division of Epidemiology and Biostatistics, Global Health Department, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Introduction: Severe bacterial infections cause significant disease burden in developing countries, including Malawi. The situation is compounded by the scarcity of resources, inconsistent availability of antibiotics, and increasing antimicrobial resistance (AMR).
Methodology: This was a descriptive retrospective study where we analyzed blood culture results of pediatric patients admitted to Kamuzu Central Hospital (KCH), Lilongwe, Malawi.
Open Forum Infect Dis
September 2025
Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA.
This retrospective cohort study evaluated short- versus long-course antibiotics for uncomplicated infections in ambulatory solid tumor patients. Among 303 patients, outcomes were similar between groups, including infection recurrence, treatment delays, and adverse events. Short-course therapy was not associated with worse outcomes, suggesting it may be a viable alternative.
View Article and Find Full Text PDFJ Infect Chemother
September 2025
Department of Infectious Diseases, Nagoya University Hospital, 466-8560, Nagoya, Aichi, Japan.
Background: Establishing the precise epidemiology of antimicrobial use (AMU) is essential to promote antimicrobial stewardship. However, data on AMU for pediatric inpatients in Japanese hospitals are lacking. In this study, we performed a subgroup analysis focusing on pediatric patients from a point prevalence survey.
View Article and Find Full Text PDF